NewGenIvf Group (NASDAQ:NIVF) Director Kong Yiu Cheung Buys 500,000 Shares of Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 500,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were purchased at an average price of $1.33 per share, with a total value of $665,000.00. Following the acquisition, the director directly owned 722,223 shares in the company, valued at approximately $960,556.59. The trade was a 225.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The shares were purchased at an average cost of $1.00 per share, for a total transaction of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung acquired 500,000 shares of NewGenIvf Group stock. The stock was acquired at an average price of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Price Performance

Shares of NewGenIvf Group stock opened at $1.21 on Thursday. NewGenIvf Group Limited has a fifty-two week low of $1.15 and a fifty-two week high of $1,539.00. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average of $2.87 and a 200 day moving average of $11.16.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.